Skip to main content
Premium Trial:

Request an Annual Quote

Fredrick Clerie, Joel McComb, Mark Smedley

Premium
Fredrick Clerie has been named vice president of quality assurance and regulatory affairs at Illumina, the company said this week. Clerie will report to Joel McComb, senior vice president and general manager of Illumina's Life Sciences Business Unit.
 
Prior to joining Illumina, Clerie served as vice president of global quality assurance and regulatory affairs for the Diagnostics Division of Bayer HealthCare, now Siemens Diagnostics. Clerie's previous role was vice president of quality assurance for the Laboratory Testing Segment of Bayer HealthCare.
 
Clerie holds a BA in biology and chemistry from Greenville College and an MS in biochemistry from the University of Illinois.
 

 
Invitrogen has named Mark Smedley, the firm’s global head of operations, to lead the integration team for its $6.7 billion acquisition of Applied Biosystems.
 
Invitrogen said in a statement that Smedley has 20 years of experience in the life sciences and pharmaceuticals industries, including a stint at drug giant Novartis, where he “led several global multi-business, multi-billion dollar integrations.”

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.